drugset / Trial / NCT01794975
Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline
Phase 1
Completed
8 enrolled
University of Turku
Orion Corporation, Orion Pharma · collabTurku University Hospital · collab
RandomizedSingle-groupSingle-blindBasic science
Summary
The primary objective of the study is to further investigate whether striatal \[11C\]ORM-13070 uptake can be reduced by physiological and pharmacological challenges that increase the synaptic concentrations of noradrenaline in the human brain. Each subject will undergo 3 PET scans, a baseline PET scan and two scans with noradrenaline challenges: intravenous administration of ketamine and oral administration of atomoxetine combined with a cold pressor test where the subject's foot is placed in an 8 °C water basin. Eight healthy male subjects will be included in the study.
Timeline
- Start
- 2012-08
- Primary completion
- 2012-12
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atomoxetine | Other / unclassified | 1.2 mg/kg | Oral |
| Comparator | Ketamine | Small molecule | — | Intravenous |
Indications
No indication recorded.